Phase 4 N=55 Mechanisms and Treatment of Intradialytic Hypertension
Intradialytic Hypertension
Primary: Endothelial Progenitor Cells — 0.052; 0.034; 0.027; 0.059 % of mononuclear cells
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=49 Tolerability of Using a Post-Treatment Topical Adjuvant Combination Following Fractional Radiofrequency Ablation
Skin Disorders
Primary: Subject Treatment Tolerability Score Post Treatment 1 at 24hrs Post Treatment — 15; 18; 7; 3 Participants
Phase 4 N=99 Efficacy of Ipack Block and Surgeon's Joint Infiltration in Total Knee Arthroplasty
Osteo Arthritis Knee
Primary: Narcotic Consumption — 15.87; 13.67 morphine equivalents, mg
Phase 3 N=94 BAY81-8973 Pediatric Safety and Efficacy Trial
Haemophilia A
Primary: Annualized Number of Total Bleeds Within 48 h — 2.23; 1.86; 1.9 Bleeds
N/A N=60 Reducing Prescription Opioid Misuse: ROPEs Pilot Trial
Knowledge, Attitudes, Practice
Primary: Methodological Feasibility: Recruitment Rate — 60 Participants
N/A N=24 Oral Immunotherapy for Peanut and Mammalian Meat Allergies
Food Hypersensitivity
Primary: The Level of Allergen Consumed Post-oral Immunotherapy — 6; 300 milligrams
N/A N=36 The Impacts of Pulmonary Rehabilitation Therapy on Patients After Thoracic Surgery
Lung Neoplasms
Primary: Discharge 2weeks Exercise Capacity — 408.61; 311.94 meter(M) — p=<0.05
Phase 1 N=92 Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin
Diabetes Mellitus
Primary: Number of Participants With Clinically Significant Physical Examination Abnormalities — 0; 0; 0; 0 participants
Phase 2 N=15 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
Chronic Inflammatory Demyelinating Polyneuropathy · Peripheral Neuropathy · Charcot-Marie-Tooth Disease
Primary: Motor Nerve Conduction Velocity (m/Sec) — 1.67 m/s — p=0.7615
Phase 2 N=24 Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
Biliary Carcinoma · Gall Bladder Carcinoma · Cholangiocarcinoma
Primary: Progression Free Survival (PFS) — 6.2 months
Phase 3 N=16 A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH
Syndrome of Inappropriate Antidiuretic Hormone Secretion
Primary: Percentage of Subjects With Normalized Serum Sodium Concentration on the Day After Final IMP Administration — 43.8; 80; 80; 85.7 percentage of participants
Phase 3 N=2,282 Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Asthma
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 88; 369; 414; 789 Participants
Phase 2 N=24 A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006)
Chronic Cough
Primary: Change From Baseline in Daytime Objective Cough Frequency — -0.5365; 0.0523 Coughs/hour — p=0.0003
N/A N=1,198 High-yield HIV Testing, Facilitated Linkage to Care, and Prevention for Female Youth in Kenya
HIV · Adolescent Behavior
Primary: Number of Newly Diagnosed Adolescent Girls and Young Women Living With HIV — 23; 9 Participants
N/A N=218 PREVAIL-TA: Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Europe)
Aortic Valve Stenosis
Primary: Number of Deaths — 16 Participants